Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Tim3”

42 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 42 results

Testing effectiveness (Phase 2)Looking for participantsNCT06125652
What this trial is testing

Administration of Anti Tim-3/CD123 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML)

Who this might be right for
Acute Myeloid Leukemia RefractoryAcute Myeloid Leukemia, in Relapse
Xuzhou Medical University 20
Testing effectiveness (Phase 2)Active Not RecruitingNCT06056895
What this trial is testing

Triple Immune Checkpoint Inhibition for Advanced or Metastatic PD-(L)1 Refractory Merkel Cell Carcinoma

Who this might be right for
Unresectable Clinical Stage III Merkel Cell Carcinoma AJCC v8Clinical Stage IV Merkel Cell Carcinoma AJCC v8Merkel Cell Carcinoma
University of Washington 12
Testing effectiveness (Phase 2)Ended earlyNCT03946670
What this trial is testing

MBG453 in Combination With Hypomethylating Agents in Subjects With IPSS-R Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS).

Who this might be right for
Myelodysplastic Syndromes
Novartis Pharmaceuticals 127
Early research (Phase 1)Active Not RecruitingNCT03961971
What this trial is testing

Trial of Anti-Tim-3 in Combination With Anti-PD-1 and SRS in Recurrent GBM

Who this might be right for
Glioblastoma Multiforme
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 16
Not applicableNot Yet RecruitingNCT07383805
What this trial is testing

Expression of Tim-3 on Neutrophils in Ankylosing Spondylitis

Who this might be right for
Ankylosing SpondylitisASTim3
Assiut University 81
Testing effectiveness (Phase 2)Active Not RecruitingNCT04823624
What this trial is testing

MBG453 in Lower Risk MDS

Who this might be right for
Myelodysplastic Syndromes
Massachusetts General Hospital 20
Testing effectiveness (Phase 2)Study completedNCT04785820
What this trial is testing

Lomvastomig (RO7121661) and Tobemstomig (RO7247669) Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus

Who this might be right for
Advanced or Metastatic Esophageal Squamous Cell Carcinoma
Hoffmann-La Roche 206
Early research (Phase 1)Study completedNCT03708328
What this trial is testing

A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors

Who this might be right for
Solid TumorsMetastatic MelanomaNon-small Cell Lung Cancer (NSCLC)+2 more
Hoffmann-La Roche 134
Large-scale testing (Phase 3)Study completedNCT01661257
What this trial is testing

Expression of TIM-3 and Correlation With Disease Activity in Pediatric Crohn's Disease With Anti TNF-α Therapy

Who this might be right for
Crohn's Disease
Samsung Medical Center 20
Early research (Phase 1)Looking for participantsNCT05357651
What this trial is testing

Assess the Safety and Efficacy of LB1410 in Participants With Advanced Solid Tumor or Lymphoma（Keyplus-001）

Who this might be right for
Solid TumorLymphoma
L & L Bio Co., Ltd., Ningbo, China 100
Testing effectiveness (Phase 2)Active Not RecruitingNCT04931654
What this trial is testing

Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer

Who this might be right for
Carcinoma, Non-Small-Cell LungGastric CancerGastroesophageal Junction Cancer
AstraZeneca 136
Large-scale testing (Phase 3)Ended earlyNCT04266301
What this trial is testing

Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)

Who this might be right for
Myelodysplastic SyndromesLeukemia, Myelomonocytic, Chronic
Novartis Pharmaceuticals 530
Testing effectiveness (Phase 2)Active Not RecruitingNCT04463771
What this trial is testing

Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy.

Who this might be right for
Endometrial Cancer
Incyte Corporation 206
Testing effectiveness (Phase 2)Active Not RecruitingNCT05287113
What this trial is testing

Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Who this might be right for
Head and Neck Cancer
Incyte Biosciences International Sàrl 176
Testing effectiveness (Phase 2)Ended earlyNCT04812548
What this trial is testing

Sabatolimab in Combination With Azacitidine and Venetoclax in High or Very High Risk MDS Participants

Who this might be right for
Myelodysplastic Syndrome (MDS)
Novartis Pharmaceuticals 20
Early research (Phase 1)Study completedNCT03489343
What this trial is testing

Sym023 (Anti-TIM-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas

Who this might be right for
Metastatic CancerSolid TumorLymphoma
Symphogen A/S 24
Not applicableStudy completedNCT03549546
What this trial is testing

Expression of the Inhibitory Receptors on Lymphocytes T Cells After Lung Cancer Surgery.

Who this might be right for
Lung CancerSurgery
Centre Hospitalier Universitaire de Saint Etienne 31
Early research (Phase 1)Study completedNCT03311412
What this trial is testing

Sym021 Monotherapy, in Combination With Sym022 or Sym023, and in Combination With Both Sym022 and Sym023 in Patients With Advanced Solid Tumor Malignancies or Lymphomas

Who this might be right for
Metastatic CancerSolid TumorLymphoma
Symphogen A/S 89
Early research (Phase 1)Ended earlyNCT03752177
What this trial is testing

LY3415244 in Participants With Advanced Solid Tumors

Who this might be right for
Solid Tumor
Eli Lilly and Company 12
Early research (Phase 1)Study completedNCT03099109
What this trial is testing

LY3321367 Alone or With LY3300054 in Participants With Advanced Relapsed/Refractory Solid Tumors

Who this might be right for
Solid Tumor
Eli Lilly and Company 209
Load More Results